CPhI Pharma Evolution to Address Practical Approaches to Process Analytical Technology in Interactive Interview with PAT Expert

NEW YORK, Aug. 14, 2013 /PRNewswire/ -- On Thursday, August 15, at 10:00 a.m. ET, CPhI Pharma Evolution's Editor-in-Chief, Agnes Shanley, will interview NIR spectroscopist and PAT expert Emil Ciurczak on practical approaches to Process Analytical Technology (PAT) in a live video chat. Since the FDA introduced the term in 2004, PAT has generated some confusion and misunderstanding among professionals in the pharmaceutical industry. Emil Ciurczak will address common myths and misconceptions, and share insights into how PAT can be implemented and used to improve efficiency and reduce quality assurance and control costs at any pharmaceutical facility.

Ciurczak was one of the first to apply PAT concepts, widely used in other industries such as chemicals and petrochemicals, and semiconductor manufacturing, to drug manufacturing and quality operations. He has worked in the pharmaceutical industry for over four decades. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies in drug manufacturing and development. His research has focused on pharmaceutical applications of NIR, and he has published more than four dozen articles in refereed journals, over 150 magazine columns, and presented nearly 200 technical papers. Ciurczak is a regular blogger on PharmaEvolution.com.

For more information and to participate in the live video chat, click here: http://www.pharmaevolution.com/video-stream.asp?section_id=3043&doc_id=560780

Next week, on Thursday, August 22, at 10:00 a.m. ET, CPhI Pharma Evolution will host a video chat on Question-Based Review (QbR) for Generics with FDA expert. For more information, click here: http://www.pharmaevolution.com/video-stream.asp?section_id=3043&doc_id=560782

Contact 
Amy Averbook 
Sr. Marketing Director
UBM DeusM
(917) 743-2693  
averbook@deusm.com

About UBM DeusM
UBM DeusM (www.deusm.com) is an integrated marketing services company owned by UBM plc, targeting the fastest growing segment of the online publishing industry: business social media. The company is led by Managing Director Stephen Saunders, Min's Marketer of the Year 2010. He and the other UBM DeusM principals have built and delivered more than 45 successful sites and online communities over the last two years. UBM DeusM's service is based on a unique platform, called Community in a Box (CiaB), which employs a structured system of proven B2B Web publishing best-practices, combined with a breakthrough integrated multimedia publishing platform ("n-Server") to enable marketers to quickly and profitably set up specialized communities for their target customers.

About CPhI
CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, China, India, Japan, Southeast Asia, Russia, Istanbul and South America co-located with ICSE for contract services, P-MEC for machinery, equipment & technology, InnoPack for pharmaceutical packaging and BioPh for biopharma. CPhI provides an online buyer & supplier directory at CPhI-Online.com and hosts a global community with news and analysis at PharmaEvolution.com.

About UBM plc
UBM plc is a leading global business media company. We inform markets and bring the world's buyers and sellers together at events, online, in print and provide them with the information they need to do business successfully. We focus on serving professional commercial communities, from doctors to game developers, from journalists to jewelry traders, from farmers to pharmacists around the world. Our 6,000 staff in more than 30 countries are organized into specialist teams that serve these communities, helping them to do business and their markets to work effectively and efficiently. For more information, go to www.ubm.com.

SOURCE CPhI Pharma Evolution